17608141|t|Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
17608141|a|Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage. In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity. Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later. Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner. As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered. Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine. We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.
17608141	15	30	methamphetamine	ChemicalEntity	D008694
17608141	53	65	dopaminergic	ChemicalEntity	D004298
17608141	66	79	neurotoxicity	DiseaseOrPhenotypicFeature	D020258
17608141	83	87	mice	OrganismTaxon	10090
17608141	91	109	lipopolysaccharide	ChemicalEntity	D008070
17608141	185	200	methamphetamine	ChemicalEntity	D008694
17608141	209	237	dopaminergic terminal damage	DiseaseOrPhenotypicFeature	D009422
17608141	279	297	lipopolysaccharide	ChemicalEntity	D008070
17608141	305	317	inflammatory	DiseaseOrPhenotypicFeature	D007249
17608141	322	334	inflammatory	DiseaseOrPhenotypicFeature	D007249
17608141	371	386	methamphetamine	ChemicalEntity	D008694
17608141	409	417	dopamine	ChemicalEntity	D004298
17608141	418	431	neurotoxicity	DiseaseOrPhenotypicFeature	D020258
17608141	433	451	Lipopolysaccharide	ChemicalEntity	D008070
17608141	510	525	methamphetamine	ChemicalEntity	D008694
17608141	535	547	hyperthermia	DiseaseOrPhenotypicFeature	D005334
17608141	580	598	lipopolysaccharide	ChemicalEntity	D008070
17608141	619	634	methamphetamine	ChemicalEntity	D008694
17608141	652	660	dopamine	ChemicalEntity	D004298
17608141	665	695	3,4-dihydroxyphenylacetic acid	ChemicalEntity	D015102
17608141	772	790	lipopolysaccharide	ChemicalEntity	D008070
17608141	847	862	methamphetamine	ChemicalEntity	D008694
17608141	879	894	methamphetamine	ChemicalEntity	D008694
17608141	912	920	dopamine	ChemicalEntity	D004298
17608141	925	955	3,4-dihydroxyphenylacetic acid	ChemicalEntity	D015102
17608141	1006	1024	lipopolysaccharide	ChemicalEntity	D008070
17608141	1065	1080	methamphetamine	ChemicalEntity	D008694
17608141	1099	1107	dopamine	ChemicalEntity	D004298
17608141	1112	1142	3,4-dihydroxyphenylacetic acid	ChemicalEntity	D015102
17608141	1212	1230	lipopolysaccharide	ChemicalEntity	D008070
17608141	1306	1321	methamphetamine	ChemicalEntity	D008694
17608141	1372	1390	lipopolysaccharide	ChemicalEntity	D008070
17608141	1445	1460	methamphetamine	ChemicalEntity	D008694
17608141	1483	1491	dopamine	ChemicalEntity	D004298
17608141	1492	1505	neurotoxicity	DiseaseOrPhenotypicFeature	D020258
17608141	Positive_Correlation	D004298	D020258	Novel
17608141	Association	D008070	D007249	No
17608141	Negative_Correlation	D008070	D020258	Novel
17608141	Association	D008070	D015102	Novel
17608141	Association	D008070	D004298	Novel
17608141	Negative_Correlation	D008070	D008694	Novel
17608141	Positive_Correlation	D008694	D009422	No
17608141	Positive_Correlation	D008694	D020258	No
17608141	Association	D008694	D015102	Novel
17608141	Association	D008694	D004298	No
17608141	Positive_Correlation	D008694	D005334	No